Related Experiment Videos

Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors

S M Storm1, U R Rapp

  • 1Frederick Cancer Research and Development Center, MD.

Toxicology Letters
|April 1, 1993
PubMed

Insights

Consistent point mutations in the c-raf-1 proto-oncogene kinase domain were found in vivo in a mouse tumor model. This discovery highlights Raf-1 as a potential target for novel anticancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Proto-oncogenes, such as c-raf-1, play crucial roles in cell signaling and can become oncogenic when mutated.
  • Activating mutations in proto-oncogenes are frequently observed in various human and animal tumors.
  • The kinase domain of Raf-1 is critical for its function and is a region of interest for oncogenic alterations.

Purpose of the Study:

  • To investigate the presence and characteristics of c-raf-1 mutations in a mouse model of chemically induced tumors.
  • To determine if activating point mutations in the kinase domain of c-raf-1 occur in vivo.
  • To assess the specificity of mutations for c-raf-1 over other proto-oncogenes like ras.

Main Methods:

  • Utilized a mouse model for chemical tumor induction.
  • Performed genetic analysis to identify point mutations in the c-raf-1 proto-oncogene within the kinase domain.
  • Examined tumor samples for mutations in c-raf-1 and related proto-oncogenes (ras).

Main Results:

  • Demonstrated consistent point mutations in the c-raf-1 proto-oncogene kinase domain in vivo.
  • This is the first report of in vivo point mutations in the raf gene and activating mutations in the kinase domain of a proto-oncogene.
  • Observed a selective specificity for Raf-1 mutations, with ras proto-oncogenes not being involved in the examined tumors.
  • Preliminary screening of human lung tumors indicated similar mutations at amino acid 533.

Conclusions:

  • Consistent in vivo mutations in the c-raf-1 kinase domain suggest its critical role in chemical carcinogenesis.
  • The findings emphasize the need to examine c-raf-1 at the sequence level for understanding human tumor development.
  • Oncogenic Raf-1 mutations highlight this enzyme as a promising target for developing new anticancer treatments.

Related Concept Videos